94 related articles for article (PubMed ID: 10697399)
1. [The usefulness of MIBI scintigraphy for postoperative monitoring of patients with thyroid cancer].
Puch Z; Handkiewicz-Junak D; Zajusz A; Orlef A; Roskosz J; Jarzab B
Pol Arch Med Wewn; 1999 Mar; 101(3):227-32. PubMed ID: 10697399
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.
Miyamoto S; Kasagi K; Misaki T; Alam MS; Konishi J
J Nucl Med; 1997 Mar; 38(3):352-6. PubMed ID: 9074516
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
[TBL] [Abstract][Full Text] [Related]
4. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile.
Nĕmec J; Nývltová O; Blazek T; Vlcek P; Racek P; Novák Z; Preiningerová M; Hubácková M; Krízo M; Zimák J; Bílek R
Eur J Nucl Med; 1996 Jan; 23(1):69-71. PubMed ID: 8586105
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
6. [A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas].
Briele B; Hotze A; Kropp J; Bockisch A; Overbeck B; Grünwald F; Kaiser W; Biersack HJ
Nuklearmedizin; 1991 Aug; 30(4):115-24. PubMed ID: 1788076
[TBL] [Abstract][Full Text] [Related]
7. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
8. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
12. Detection of recurrent malignant melanoma with 99mTc-MIBI scintigraphy.
Alonso O; Martinez M; Mut F; Delgado L; Lago G; De Boni D; Bazzano C; Núñez M; Garcés M; Muse IM; Roca R; Touya E; Espasandín J; Priario J
Melanoma Res; 1998 Aug; 8(4):355-60. PubMed ID: 9764811
[TBL] [Abstract][Full Text] [Related]
13. Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin.
Adalet I; Koçak M; Ogŭz H; Alagöl F; Cantez S
Nucl Med Commun; 1999 Apr; 20(4):353-9. PubMed ID: 10319355
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
[TBL] [Abstract][Full Text] [Related]
15. [99mTc Tetrofosmin in diagnosis of distant metastases from differentiated thyroid cancer].
Drac-Kaniewska J; Kozłowicz-Gudzińska I; Tomaszewicz-Kubasik H; Kaniewski M; Godlewska P; Czetwertyńska M; Chaładaj-Kujawska A
Wiad Lek; 2001; 54 Suppl 1():357-62. PubMed ID: 12182048
[TBL] [Abstract][Full Text] [Related]
16. Tc-99m MIBI scintigraphic detection of metastatic insular thyroid carcinoma.
Zak IT; Seabold JE; Gurll NJ
Clin Nucl Med; 1995 Jan; 20(1):31-6. PubMed ID: 7895433
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma.
Uğur O; Kostakoğlu L; Caner B; Güler N; Gülaldi NC; Ozmen M; Uysal U; Elahi N; Erbengi G; Bejdik C
Nucl Med Commun; 1996 May; 17(5):373-7. PubMed ID: 8736512
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
